Skip to main content

Advertisement

Table 1 Baseline characteristics

From: Effects of 8,000 IU aXa long-term prophylaxis with certoparin on the incidence of hyperkalemia in patients with coronary heart disease – a post-hoc analysis of the PARAT trial

   Certoparin (n = 59) Placebo (n = 58)
Age (years) Mean ± SD 60.0 ± 10.0 57.5 ± 11.2
  Min 41 31
  Max 78 79
Gender (%) Male 83.1 86.2
Race Caucasean 52 51
  Black 5 7
  Hispanic 2 0
K+ at baseline (mmol/l) Mean ± SD 4.2 ± 0.4 4.3 ± 0.4
  Min 3.4 3.5
  Max 5.4 5.0
Diabetes mellitus (%) 28.8 19.0
Blood urea (mmol/l) Mean ± SD 16.5 ± 5.3 16.0 ± 5.6
  Min 7.0 7.0
  Max 31.0 37.0
Serum creatinine (mg/dl) Mean ± SD 1.1 ± 0.2 1.1 ± 0.3
  Min 0.7 0.7
  Max 1.6 2.0
eGFR (ml/min) Mean ± SD 95.7 ± 35.5 97.5 ± 32.7
  Min 43.2 41.81
  Max 208.06 186.48